Navigation Links
AtheroNova Completes Successful Pre-IND Meeting with FDA on AHRO-001
Date:10/26/2011

IRVINE, Calif., Oct. 26, 2011 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, today announced that it has completed its pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA). During the meeting, the FDA provided guidance on the development plan of AHRO-001, AtheroNova's lead patent-pending compound for the prevention and regression of atherosclerotic plaque. The goal of the pre-IND meeting was to obtain clarification on the nonclinical, clinical and chemical, manufacturing and control (CMC) requirements that need to be met in order to submit an acceptable IND.

"Our meeting with the FDA represents another important step in our clinical drug development plan. Our strategy to bring AHRO-001 into human clinical trials is now clear," said AtheroNova CEO Thomas Gardner. "Combined with our recent commitment from Maxwell Biotech Venture Fund to fund both Phase I and Phase II clinical trials and our licensing partnership with Maxwell Biotech Group, we are on track to commercialize novel therapies that can help millions of those suffering from cardiovascular disease."

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain natural compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are then removed by natural body processes. AtheroNova plans to develop multiple applications for its patents-pending compounds that can be used in pharmaceutical-grade products for the treatment of atherosclerosis. Atherosclerosis and related pharmaceutical costs run more than $41 billion annually in the United States alone.  Marke
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014 The global high content screening market ... ,Threat of Obsolescence, wherein technologies as well as their ... biotechnology companies as well as academic and government institutes ... a powerful research tool in drug discovery. The high ... the high content screening market. In high content screening, ...
(Date:10/1/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... agreement with Patterson Veterinary Supply. Patterson ... of Abaxis veterinary products throughout the United ...
(Date:10/1/2014)... BOSTON , Oct. 1, 2014   ... market-leading provider of Anesthesia Information Management Systems (AIMS), ... Systems, LLC , a wholly owned subsidiary of ... healthcare information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
... , , , LIBERTYVILLE, Ill., ... today that the Office of Orphan Products Development of the Food ... for the treatment of Spinal Muscular Atrophy. , , ... for Spinal Muscular Atrophy has ever reached the important stage of ...
... , , , ... Forest Laboratories today announced that results of four phase III ... The Lancet showing that roflumilast, a phosphodiesterase 4 ... to severe COPD. , , COPD is ...
Cached Medicine Technology:Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 2Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 3Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 2Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 3Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 5Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 6Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 7Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 8Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 9
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, ... out all the stops to rescue surgical patients in ... cost of such heroism is questionable, a new study ... better at saving elderly patients with life-threatening complications after ... intensity, said senior author Dr. Amir Ghaferi. He is ...
(Date:10/1/2014)... that more than 80 per cent of bowel cancers ... found that medicines called ,JAK inhibitors, halted tumour growth ... present in more than 80 per cent of bowel ... in clinical trials, for diseases including rheumatoid arthritis, psoriasis, ... the second-most common cancer in Australia with nearly 17,000 ...
(Date:10/1/2014)... Despite a policy focus on expanding access to ... population continues to have significant dental disease. In ... the American Dental Association , researchers from Tufts ... of Dental Medicine report on the first large-scale ... provided by caregivers to adults with developmental disabilities. ...
(Date:10/1/2014)... 01, 2014 Bedros Keuilian is not ... Camp fitness boot camps, he’s also considered the leading ... with sold out business summits, a line of high-demand ... to a recent Spike TV reality show to his ... is the time for personal trainers and fitness business ...
(Date:10/1/2014)... FARMINGTON, Conn. (PRWEB) October 01, 2014 ... its company, including a redefined mission and visual ... the power of partnering with them to create ... more agile brand that focuses on empowering customers ... benefits communications. , The crown jewel of the ...
Breaking Medicine News(10 mins):Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2
... internet about human incidence of bird flu in Quebec is ... ,Dr Patrick Dolce, the man at the helm ... "Everything is false; there is no patient, no nothing." ... devoted to avian flu which had enabled a report of ...
... C last week. Public health department in Toronto has alerted ... contagious and the man who died happened to have frequented ... ,Although only a single case has been notified, owing to ... public to be cautious.,Meningitis C is a contagious disease caused ...
... about memory could offer an early warning system for ... at Rush University Medical Center. The researchers have found// ... changes in the brain related to Alzheimer's disease. Their ... Neurology. ,The researchers looked at the association ...
... for termination of early pregnancies, might be helpful to ... from the University of California, whose work has been ... licensed drug that blocks the hormone progesterone. In pregnancy, ... If it is depleted the developing fetus can get ...
... and colleagues at four other medical centers have launched ... may contribute to early atherosclerosis. ,“If we can ... who have a genetic predisposition to develop atherosclerosis, we ... stroke sooner and more aggressively,” said David Herrington, M.D., ...
... an imbalance in the overall treatment has lead to the ... of effective dietary care are met with. ,According ... not yet analyzed the nutritional value of the diets the ... any miscalculation in their prescription of menus can lead to ...
Cached Medicine News:Health News:Memory Complaints Are Associated With Alzheimer's Disease 2Health News:Memory Complaints Are Associated With Alzheimer's Disease 3Health News:Breast Cancer Prevention Using Abortion Drug Considered 2Health News:Study Underway to Identify Genes Contributing to Heart Attack Risk 2Health News:Hospital Food Needs Improvement to Meet the Nutritional Needs of the Patient 2
2 mm wide curved tip. Round handle....
3 mm disposable Lance blade. Can fit in to the N0521 Storz handle....
Consist of 6 disposable bevel blades (N0522) and chuck handle (0521). Malleable shafts. Designated most popular model or size....
1.5 mm x 12 mm tip. Angled 15 degrees. Teflon coated with diathermy attachment....
Medicine Products: